CRSPUSNASDAQ / NYSE · United States
CRISPR THERAPEUTICS LTD.
42.24USD-0.89%close 2026-11-13
Daily candles · 12 months
CRSP · 1DPerformance
1W
-15.6%1M
-18.0%3M
-22.2%6M
-12.7%YTD
-19.5%1Y
-19.6%52W low 41.75high 63.45
-33.4% from the 52-week high.
Trend
- vs 20-day average
- Below by 14.3%
- vs 50-day average
- Below by 18.9%
- vs 200-day average
- Below by 19.6%
- ATR (14d)
- 6.80%
- 10-day range
- 25.4%
- Volume vs 20-day avg
- 1.17×
Position size
- Risk per share
- 4.31 USD
- Shares
- 23
- Position value
- 971.52 USD
- % of account
- 9.7%
- Risk amount
- 99.13 USD
- 1R target
- 46.55
- 2R target
- 50.86
- 3R target
- 55.17
Fundamentals and earnings
- Market cap
- 4.10B
- P/E (trailing)
- –
- P/E (forward)
- -11.5
- EPS (TTM / next yr)
- -4.69 / -3.69
- Dividend yield
- –
- Earnings date
- Nov 2, 2026
Listing
- Ticker
- CRSP US
- Yahoo / TradingView
- CRSP · NASDAQ:CRSP
- Keyword
- KGI TAIWAN HD 30 ETF
Headlines
- CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026GlobeNewswire · 5d ago
- CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune DiseasesGlobeNewswire · 6d ago
- CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on ItZacks · 8d ago
- CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswire · 10d ago
- Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies AheadInvestor's Business Daily · 10d ago
- Why Did CRISPR Therapeutics (CRSP) Stock Slide After Its Latest Update?Simply Wall St. · 10d ago
Prices and fundamentals from Yahoo Finance, delayed. Not financial advice.